AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR-mutated lung cancer. However, some patients show intrinsic resistance and an insufficient response to osimertinib. This study showed that osimertinib stimulated AXL by inhibiting a negative feedback...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Hirokazu, Yamada, Tadaaki, Wang, Rong, Tanimura, Keiko, Adachi, Yuta, Nishiyama, Akihiro, Tanimoto, Azusa, Takeuchi, Shinji, Araujo, Luiz H., Boroni, Mariana, Yoshimura, Akihiro, Shiotsu, Shinsuke, Matsumoto, Isao, Watanabe, Satoshi, Kikuchi, Toshiaki, Miura, Satoru, Tanaka, Hiroshi, Kitazaki, Takeshi, Yamaguchi, Hiroyuki, Mukae, Hiroshi, Uchino, Junji, Uehara, Hisanori, Takayama, Koichi, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335418/
https://www.ncbi.nlm.nih.gov/pubmed/30651547
http://dx.doi.org/10.1038/s41467-018-08074-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335418/
https://www.ncbi.nlm.nih.gov/pubmed/30651547
http://dx.doi.org/10.1038/s41467-018-08074-0

Ejemplares similares